Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study

Scaldazza, C. Vecchioli; Morosetti, Carolina

doi:10.1159/000445808

Cited by 19 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, three studies were excluded because they had been published in a different periodical. Finally, five articles containing five RCTs were included in our study to analyze mirabegron and solifenacin monotherapy for OAB treatment. The baseline characteristics of these five studies are summarized in Table .…”

Section: Resultsmentioning

confidence: 99%

“…The sample capacity was calculated (Table ). Scaldazza et al is not a double‐blinded design, so that the grade of the blinding method was “B,” and each of the other studies was grated as “A.”…”

Section: Resultsmentioning

confidence: 99%

“…Mirabegron and solifenacin can relax the detrusor muscle by inhibiting β3‐adrenoceptors or muscarinic‐3 receptors, respectively, thereby regulating the storage and expulsion of urine . Scaldazza et al found that mirabegron and solifenacin improved the storage function in a pressure‐flow study, but solifenacin showed a reduction in the detrusor pressure in the voiding phase.…”

Section: Discussionmentioning

confidence: 99%

“…Our meta‐analysis involved five RCTs and the quality of each RCT was high. Scaldazza et al is not a double‐blinded design, which may affect the objectivity of the results and cause subjective bias. We could not infer the long‐term efficacy, safety, and tolerance of mirabegron and solifenacin monotherapy, and our meta‐analysis may have suffered from selection bias.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Meta‐analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder

Wang

Zhou

Cui

et al. 2018

Neurourology and Urodynamics

View full text Add to dashboard Cite

Aim:We conducted a meta-analysis to evaluate the safety and efficacy of mirabegron (50 mg) and solifenacin (5 mg) monotherapy for overactive bladder (OAB) during a 12-week cycle. Methods: Randomized controlled trials (RCTs) of mirabegron and solifenacin for OAB were searched systematically by using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The reference lists of retrieved studies were also perused. Results: Five RCTs which compared solifenacin with mirabegron were studied.Mirabegron achieved the same effect as solifenacin in treating OAB. The mean number of incontinence episodes per 24 h (P = 0.20), mean number of micturitions per 24 h (P = 0.11), mean number of urgency episodes per 24 h (P = 0.23), and mean volume voided per micturition (P = 0.05) suggested that mirabegron and solifenacin had no significant differences in terms of OAB treatment. With regard to drug-related treatment-emergent adverse events (DR-TEAEs) and dry mouth, mirabegron showed better tolerance than solifenacin. Post-voiding residual volume showed a distinct difference in the two groups. Hypertension and tachycardia did not show a significant difference between the two groups, but the pulse rate did. Conclusion: The therapeutic effect of mirabegron is similar to that of solifenacin, and mirabegron does not increase the risk of adverse events (AEs). K E Y W O R D Smeta-analysis, mirabegron, overactive bladder, randomized controlled trials, solifenacin

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Meta‐analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder

Wang

Zhou

Cui

et al. 2018

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…The urodynamic effects of antimuscarinic agents in OAB and NLUTD have been well documented in previous studies [26], but the clinical experience and evidence of mirabegron efficacy as demonstrated by UDS are still inadequate. Matsukawa et al [27] and Vecchioli Scaldazza and Morosetti [28] reported a significant increase in cystometric capacity by an average of 37 mL and 41 mL, respectively, in women with OAB who received mirabegron 50 mg once a day for 12 weeks. In a study involving men with OAB, mirabegron add-on therapy with tamsulosin significantly increased cystometric capacity (by 24%, from 170 to 212 mL) [29].…”

Section: Discussionmentioning

confidence: 99%

Long-Term Efficacy of Mirabegron Add-On Therapy to Antimuscarinic Agents in Patients With Spinal Cord Injury

et al. 2019

View full text Add to dashboard Cite

ObjectiveTo evaluate the long-term efficacy of mirabegron add-on therapy in patients with spinal cord injury (SCI) based on an urodynamic study.MethodsThis retrospective study involved a chart audit of individuals with SCI who underwent two consecutive urodynamic studies between April 1, 2015 and April 1, 2018. After adding 50 mg of mirabegron once a day to the pre-existing antimuscarinic therapy for a period of, at least 6 months, the following variables were analyzed: change in cystometric capacity, change in bladder compliance, change in maximal detrusor pressure, change in reflex volume, and presence of significant leakage during filling cystometry.ResultsA total of 31 participants with a mean age of 41±15 years were included in the analysis. A significant increase in cystometric capacity (mean, 362 to 424 mL; p=0.03), reflex volume (mean, 251 to 329 mL; p=0.02), and bladder compliance (median, 12 to 18 mL/cmH2O; p=0.04) was observed. The presence of leakage during filling cystometry was significantly reduced (29% to 10%; p=0.03). Likewise, a non-significant decrease in the change in maximal detrusor pressure was observed (mean, 31 to 27 cmH2O; p=0.39).ConclusionAdding mirabegron to conventional antimuscarinics further improved urodynamic parameters in patients with chronic SCI, and sustained efficacy was observed in long-term use.

show abstract

Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults

Stoniute

Madhuvrata

Still

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundAround 16% of adults have symptoms of overactive bladder (OAB; urgency with frequency and/or urge incontinence), with prevalence increasing with age. Anticholinergic drugs are commonly used to treat this condition. This is an update of a Cochrane Review first published in 2002 and last updated in 2006. ObjectivesTo assess the e ects of anticholinergic drugs compared with placebo or no treatment for treating overactive bladder syndrome in adults. Search methodsWe searched the Cochrane Incontinence Specialised Register, which contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, MEDLINE Epub Ahead of Print, ClinicalTrials.gov, WHO ICTRP and handsearching of journals and conference proceedings (searched 14 January 2020), and the reference lists of relevant articles. We updated this search on 3 May 2022, but these results have not yet been fully incorporated. Selection criteriaWe included randomised or quasi-randomised trials in adults with overactive bladder syndrome that compared an anticholinergic drug alone with placebo treatment. Data collection and analysisTwo review authors independently assessed eligibility and extracted data from the included studies, including an assessment of the risk of bias. We assessed the certainty of the body of evidence using the GRADE approach. We processed data as described in the Cochrane Handbook for Systematic Reviews of Interventions. Main resultsWe included 104 studies, 71 of which were new or updated for this version of the review. Although 12 studies did not report the number of participants, there were 47,106 people in the remainder of the included studies. The majority of the studies had insu icient information to Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults (Review)

show abstract

Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study

Cited by 19 publications

References 25 publications

Meta‐analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder

Meta‐analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder

Long-Term Efficacy of Mirabegron Add-On Therapy to Antimuscarinic Agents in Patients With Spinal Cord Injury

Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults

Contact Info

Product

Resources

About